Julien Meyrat | 15 février 2016 |
Almost one tenth of European pharmaceutical R&D investment in 2014 took place in Belgium.
According to a study by pharma.be, almost one tenth of European pharmaceutical R&D investment in 2014 took place in Belgium (2.3 billion euros, second only to Denmark in terms of population).
The country is one of the EU’s main biopharmaceutical hubs, generating almost one-sixth of European drug exports. The Belgian sector boasts over 200 pharmaceutical companies and more than 34,000 employees.
In July 2015, the pharmaceutical industry signed a “pact for the future” with the federal government, aimed at consolidating its strong position (easier access to recent treatments, modernization of procedures, etc.).
The study is available online.
The Belgian biopharmaceutical sector in figures
Over 200 pharmaceutical companies
34,000 highly skilled workers
A unique ecosystem of multinationals, biotech firms and specialized SMEs
Close collaboration with universities and research centers
2.3 billion euros invested in R&D (2014)
A magnet for clinical trials: no. 1 in Europe and no. 2 worldwide*.
A unique geostrategic location: an asset for distribution in Europe
* Based on the number of clinical trials per capita
Source: Pharma figures 2014, Clinical trial.gov (September 2014) www.processpropre.fr